FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3155116475> ?p ?o ?g. }

• W3155116475 endingPage "1643" @default.
• W3155116475 startingPage "1643" @default.
• W3155116475 abstract "Abstract Background: Single cases of aggressive B-cell non-Hodgkin lymphomas upon treatment with the Janus kinase 1/2 (JAK1/2) inhibitor ruxolitinib in patients with myeloproliferative disorders (MPD) have been reported (Pardanani, Mayo Clin.Proc. 2011 ; Bhatt VR et al. J Natl Compr Canc Netw . 2015;13(3):281-28; Palmason et al. BMC Hematology 2015). However, incidence and pathogenesis remain enigmatic. Methods: We investigated 626 patients with myeloproliferative neoplasms diagnosed at the Medical University of Vienna between 1997 and 2016. Of these, 69 patients with primary or secondary myelofibrosis were treated with JAK2 -inhibitors since 2009. Data on secondary malignancies were retrieved from our MPN database. Detailed clinical, pathologic and genetic data were obtained in patients developing lymphoma. These observations were recapitulated in a Stat1 knock-out mouse model (Stat1-/- mice). Results: B-cell lymphomas developed in 4 out of 69 patients (5.8%) upon ruxolitinib treatment compared to only 2 of 557 (0.36%) in the control group (16-fold increased risk, p=0.0017). The median time to lymphoma diagnosis was 25 months after ruxolitinib initiation (Table 1). Two lymphoma patients had been pre-treated with alkylating agents before ruxolitinib, one with hydroxyurea, the JAK -inhibitor fedratinib and ruxolitinib, and one received ruxolitinib only. All lymphomas were of aggressive CD19+ B-cell type (3 DLBCL, 1 HG BCL NOS) and showed distinct features with extranodal involvement and/or bone marrow infiltration (3/4), IPI of 2 or greater, and high MYC, and TP53 expression. Genetic analysis revealed abnormalities in MYC, BCL2, BCL6 or TP53 genes (Table 1). Targeted sequencing in 2 patients showed inactivating mutations in the B2M, CDKN2A, or TP53 genes. No JAK2 -mutation was found in the lymphomas. Three of four patients responded to anti-lymphoma therapy, but 3 patients eventually died from lymphoma or sAML. Of note, the clinical, and pathogenetic features closely resembled those of the published cases and 2 cases seen at a different institution (Paris, Hospital Saint-Louis). Mice deficient for the JAK kinase target STAT1 mirrored the course of the human disease: 16 of 24 Stat1-/- mice developed myeloid hyperplasia with splenomegaly and a massive expansion of myeloid blasts in bone marrow and peripheral blood. Lowering the load of myeloid blasts by ATRA or ruxolitinib led to B-cell proliferation. Transplantation of bone marrow from diseased Stat1-/- mice resulted in aggressive B-cell lymphomas displaying strikingly similar features to the human lymphomas with upregulation of c-Myc and Bcl-2 and downregulation of B2m (s2-microglobulin) and Cdkn2a . STAT3 and STAT5 were not activated in these B-cell lymphomas indicating that the JAK/STAT pathway is dispensable for B cell transformation. B cells from diseased Stat1-/- mice gave rise to stable growth-factor independent cell lines, underlining their high grade of transformation. Conclusion. Inhibition of the JAK/STAT1 pathway in myeloproliferative diseases appears to provoke the development of a distinct type of aggressive B-cell lymphoma. In myelofibrosis treated with a JAK2 inhibitor 5 to 6% of patients are affected. Further investigations to identify potential risk factors are ongoing. Download : Download high-res image (219KB) Download : Download full-size image Table 1 . Disclosures Sperr: Celgene: Consultancy, Honoraria; Amgen: Consultancy, Honoraria, Research Funding; Phadia: Research Funding; Meda: Research Funding; Teva: Honoraria; Novartis: Other: Register. Staber: Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees; Gilad: Honoraria, Membership on an entity's Board of Directors or advisory committees; Morphosys: Membership on an entity's Board of Directors or advisory committees; Abbie: Honoraria, Membership on an entity's Board of Directors or advisory committees; Takeda: Honoraria; MSD: Honoraria; Amgen: Honoraria; Roche: Honoraria, Membership on an entity's Board of Directors or advisory committees. Valent: Blueprint: Research Funding; Novartis: Honoraria, Research Funding; Celgene: Honoraria, Research Funding; Incyte: Honoraria; BMS: Honoraria; Ariad: Honoraria, Research Funding; Pfizer: Honoraria; Teva: Honoraria; Deciphera: Honoraria, Research Funding. Hoermann: Gilead: Honoraria, Research Funding; Ariad: Honoraria; Amgen: Honoraria; Novartis: Honoraria. Kiladjian: Novartis: Membership on an entity's Board of Directors or advisory committees, Research Funding; AOP Orphan: Membership on an entity's Board of Directors or advisory committees, Research Funding; Celgene: Membership on an entity's Board of Directors or advisory committees. Krauth: Novartis: Honoraria; Celgene: Honoraria; AOP Orphan Pharmaceuticals AG: Honoraria; BMS: Honoraria; Takeda: Honoraria; Janssen Cilag: Honoraria; Amgen: Honoraria. Jaeger: Janssen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel, Accommodations, Expenses; Roche: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel, Accommodations, Expenses; Novartis Pharmaceuticals Corporation: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Celgene: Honoraria, Membership on an entity's Board of Directors or advisory committees. Gisslinger: PharmaEssentia: Consultancy, Honoraria; AOP Orphan Pharmaceuticals AG: Consultancy, Honoraria; Novartis: Consultancy, Honoraria; Shire: Honoraria; Janssen Cilag: Honoraria; Takeda: Honoraria." @default.
• W3155116475 created "2021-04-26" @default.
• W3155116475 creator A5003619359 @default.
• W3155116475 creator A5006306448 @default.
• W3155116475 creator A5007091163 @default.
• W3155116475 creator A5007353369 @default.
• W3155116475 creator A5008008223 @default.
• W3155116475 creator A5008609620 @default.
• W3155116475 creator A5009837774 @default.
• W3155116475 creator A5012645543 @default.
• W3155116475 creator A5016041137 @default.
• W3155116475 creator A5018036942 @default.
• W3155116475 creator A5023876256 @default.
• W3155116475 creator A5026124941 @default.
• W3155116475 creator A5027978059 @default.
• W3155116475 creator A5034454190 @default.
• W3155116475 creator A5036988600 @default.
• W3155116475 creator A5038160508 @default.
• W3155116475 creator A5039806772 @default.
• W3155116475 creator A5042463876 @default.
• W3155116475 creator A5049331182 @default.
• W3155116475 creator A5058033139 @default.
• W3155116475 creator A5059496734 @default.
• W3155116475 creator A5069697353 @default.
• W3155116475 creator A5069948566 @default.
• W3155116475 creator A5072949561 @default.
• W3155116475 creator A5073807974 @default.
• W3155116475 creator A5078054916 @default.
• W3155116475 creator A5078621047 @default.
• W3155116475 creator A5079620940 @default.
• W3155116475 creator A5088392460 @default.
• W3155116475 date "2017-12-07" @default.
• W3155116475 modified "2023-10-01" @default.
• W3155116475 title "JAK2-Inhibitor Therapy Associated Lymphomas in Myelofibrosis: Distinct Clinico-Pathological Features Recapitulated in a Mouse Model" @default.
• W3155116475 doi "https://doi.org/10.1182/blood.v130.suppl_1.1643.1643" @default.
• W3155116475 hasPublicationYear "2017" @default.
• W3155116475 type Work @default.
• W3155116475 sameAs 3155116475 @default.
• W3155116475 citedByCount "0" @default.
• W3155116475 crossrefType "journal-article" @default.
• W3155116475 hasAuthorship W3155116475A5003619359 @default.
• W3155116475 hasAuthorship W3155116475A5006306448 @default.
• W3155116475 hasAuthorship W3155116475A5007091163 @default.
• W3155116475 hasAuthorship W3155116475A5007353369 @default.
• W3155116475 hasAuthorship W3155116475A5008008223 @default.
• W3155116475 hasAuthorship W3155116475A5008609620 @default.
• W3155116475 hasAuthorship W3155116475A5009837774 @default.
• W3155116475 hasAuthorship W3155116475A5012645543 @default.
• W3155116475 hasAuthorship W3155116475A5016041137 @default.
• W3155116475 hasAuthorship W3155116475A5018036942 @default.
• W3155116475 hasAuthorship W3155116475A5023876256 @default.
• W3155116475 hasAuthorship W3155116475A5026124941 @default.
• W3155116475 hasAuthorship W3155116475A5027978059 @default.
• W3155116475 hasAuthorship W3155116475A5034454190 @default.
• W3155116475 hasAuthorship W3155116475A5036988600 @default.
• W3155116475 hasAuthorship W3155116475A5038160508 @default.
• W3155116475 hasAuthorship W3155116475A5039806772 @default.
• W3155116475 hasAuthorship W3155116475A5042463876 @default.
• W3155116475 hasAuthorship W3155116475A5049331182 @default.
• W3155116475 hasAuthorship W3155116475A5058033139 @default.
• W3155116475 hasAuthorship W3155116475A5059496734 @default.
• W3155116475 hasAuthorship W3155116475A5069697353 @default.
• W3155116475 hasAuthorship W3155116475A5069948566 @default.
• W3155116475 hasAuthorship W3155116475A5072949561 @default.
• W3155116475 hasAuthorship W3155116475A5073807974 @default.
• W3155116475 hasAuthorship W3155116475A5078054916 @default.
• W3155116475 hasAuthorship W3155116475A5078621047 @default.
• W3155116475 hasAuthorship W3155116475A5079620940 @default.
• W3155116475 hasAuthorship W3155116475A5088392460 @default.
• W3155116475 hasConcept C126322002 @default.
• W3155116475 hasConcept C142724271 @default.
• W3155116475 hasConcept C143998085 @default.
• W3155116475 hasConcept C159654299 @default.
• W3155116475 hasConcept C194409129 @default.
• W3155116475 hasConcept C203014093 @default.
• W3155116475 hasConcept C2776112149 @default.
• W3155116475 hasConcept C2777537477 @default.
• W3155116475 hasConcept C2778453870 @default.
• W3155116475 hasConcept C2779338263 @default.
• W3155116475 hasConcept C2780007613 @default.
• W3155116475 hasConcept C2780076729 @default.
• W3155116475 hasConcept C502942594 @default.
• W3155116475 hasConcept C71924100 @default.
• W3155116475 hasConcept C96926380 @default.
• W3155116475 hasConceptScore W3155116475C126322002 @default.
• W3155116475 hasConceptScore W3155116475C142724271 @default.
• W3155116475 hasConceptScore W3155116475C143998085 @default.
• W3155116475 hasConceptScore W3155116475C159654299 @default.
• W3155116475 hasConceptScore W3155116475C194409129 @default.
• W3155116475 hasConceptScore W3155116475C203014093 @default.
• W3155116475 hasConceptScore W3155116475C2776112149 @default.
• W3155116475 hasConceptScore W3155116475C2777537477 @default.
• W3155116475 hasConceptScore W3155116475C2778453870 @default.
• W3155116475 hasConceptScore W3155116475C2779338263 @default.
• W3155116475 hasConceptScore W3155116475C2780007613 @default.
• W3155116475 hasConceptScore W3155116475C2780076729 @default.
• W3155116475 hasConceptScore W3155116475C502942594 @default.
• W3155116475 hasConceptScore W3155116475C71924100 @default.

• next